001     280021
005     20250824001702.0
024 7 _ |a 10.1002/alz.70367
|2 doi
024 7 _ |a pmid:40673371
|2 pmid
024 7 _ |a 1552-5260
|2 ISSN
024 7 _ |a 1552-5279
|2 ISSN
024 7 _ |a altmetric:179480775
|2 altmetric
037 _ _ |a DZNE-2025-00865
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Bouzigues, Arabella
|0 0000-0002-0267-8590
|b 0
245 _ _ |a Structural and functional connectivity in tau mutation carriers: from presymptomatic to symptomatic frontotemporal dementia.
260 _ _ |a Hoboken, NJ
|c 2025
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1755681259_25773
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Microtubule-associated protein tau (MAPT) mutations cause frontotemporal dementia (FTD), characterised by behavioural, language, and motor impairments due to brain connectivity disruptions. We investigated structural and functional connectivity in 86 mutation carriers and 272 controls to map connectivity changes at different disease stages.The CDR Dementia Staging Instrument plus National Alzheimer's Coordinating Center (NACC) Behaviour and Language domains (CDR plus NACC FTLD) stratified carriers into three groups: asymptomatic, prodromal, and symptomatic. We extracted measures of cortical thickness, white matter integrity, and functional connectivity, which were compared between each carrier group and controls using linear mixed models.Early isolated functional disruptions in salience/visual networks were present in asymptomatic carriers, along with anterior cingulate gray matter reductions. In prodromal carriers, functional changes extended to other networks, with additional structural damage in temporal poles/cingulate.This study shows that functional networks likely drive lifelong compensation for a genetically determined disease, manifesting clinically when structural damage reaches a critical threshold. This supports connectivity measures as potential biomarkers for MAPT-related neurodegeneration.Our findings reveal the progressive and staged nature of structural and functional connectivity alterations in MAPT mutation carriers, with distinct patterns at each disease stage. In asymptomatic carriers, we identified early functional connectivity alterations in salience and visual networks, despite preserved white matter and only subtle gray matter atrophy. These appear to represent both response to pathology and possible compensatory mechanisms. In prodromal carriers, functional connectivity alterations were accompanied by structural damage, including cortical atrophy and white matter tract disruptions, in regions directly connected to early-affected networks. The sequential progression, from functional connectivity changes to structural degeneration, aligns with the hypothesis that tau propagates along axonal connections, disrupting neural network integrity before measurable atrophy occurs. We propose a theoretical data-driven model of biomarker evolution in MAPT mutation carriers, highlighting functional disruptions as early indicators and structural damage as a later-stage hallmark. These connectivity biomarkers have the potential to inform therapeutic strategies and clinical trial design.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a MAPT
|2 Other
650 _ 7 |a functional connectivity
|2 Other
650 _ 7 |a genetic frontotemporal dementia
|2 Other
650 _ 7 |a graph analysis
|2 Other
650 _ 7 |a gray matter
|2 Other
650 _ 7 |a macroscale organization
|2 Other
650 _ 7 |a mutation
|2 Other
650 _ 7 |a neurodegeneration
|2 Other
650 _ 7 |a tau
|2 Other
650 _ 7 |a tau pathology
|2 Other
650 _ 7 |a white matter
|2 Other
650 _ 7 |a tau Proteins
|2 NLM Chemicals
650 _ 7 |a MAPT protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: genetics
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: pathology
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: physiopathology
|2 MeSH
650 _ 2 |a Frontotemporal Dementia: diagnostic imaging
|2 MeSH
650 _ 2 |a tau Proteins: genetics
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Mutation: genetics
|2 MeSH
650 _ 2 |a Magnetic Resonance Imaging
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a White Matter: pathology
|2 MeSH
650 _ 2 |a White Matter: diagnostic imaging
|2 MeSH
650 _ 2 |a Heterozygote
|2 MeSH
650 _ 2 |a Brain: pathology
|2 MeSH
650 _ 2 |a Brain: physiopathology
|2 MeSH
650 _ 2 |a Brain: diagnostic imaging
|2 MeSH
650 _ 2 |a Prodromal Symptoms
|2 MeSH
700 1 _ |a Du, Vincent Le
|b 1
700 1 _ |a Joulot, Matthieu
|b 2
700 1 _ |a Peysson, Ninon
|b 3
700 1 _ |a Houot, Marion
|b 4
700 1 _ |a Béranger, Benoît
|b 5
700 1 _ |a Russell, Lucy L
|b 6
700 1 _ |a Foster, Phoebe H
|b 7
700 1 _ |a Ferry-Bolder, Eve
|b 8
700 1 _ |a van Swieten, John C
|b 9
700 1 _ |a Jiskoot, Lize
|b 10
700 1 _ |a Seelaar, Harro
|b 11
700 1 _ |a Sanchez-Valle, Raquel
|b 12
700 1 _ |a Laforce, Robert
|b 13
700 1 _ |a Graff, Caroline
|b 14
700 1 _ |a Galimberti, Daniela
|b 15
700 1 _ |a Vandenberghe, Rik
|b 16
700 1 _ |a de Mendonça, Alexandre
|b 17
700 1 _ |a Tiraboschi, Pietro
|b 18
700 1 _ |a Santana, Isabel
|b 19
700 1 _ |a Gerhard, Alexander
|b 20
700 1 _ |a Levin, Johannes
|0 P:(DE-2719)2811659
|b 21
|u dzne
700 1 _ |a Sorbi, Sandro
|b 22
700 1 _ |a Otto, Markus
|b 23
700 1 _ |a Bertoux, Maxime
|b 24
700 1 _ |a Lebouvier, Thibaud
|b 25
700 1 _ |a Ducharme, Simon
|b 26
700 1 _ |a Butler, Chris R
|b 27
700 1 _ |a Ber, Isabelle Le
|b 28
700 1 _ |a Finger, Elizabeth
|b 29
700 1 _ |a Tartaglia, Maria Carmela
|b 30
700 1 _ |a Masellis, Mario
|b 31
700 1 _ |a Rowe, James B
|b 32
700 1 _ |a Synofzik, Matthis
|0 P:(DE-2719)2811275
|b 33
|u dzne
700 1 _ |a Moreno, Fermin
|b 34
700 1 _ |a Borroni, Barbara
|b 35
700 1 _ |a Rohrer, Jonathan D
|b 36
700 1 _ |a Migliaccio, Raffaella
|b 37
700 1 _ |a Initiative, GENetic Frontotemporal dementia
|b 38
|e Collaboration Author
773 _ _ |a 10.1002/alz.70367
|g Vol. 21, no. 7, p. e70367
|0 PERI:(DE-600)2201940-6
|n 7
|p e70367
|t Alzheimer's and dementia
|v 21
|y 2025
|x 1552-5260
856 4 _ |u https://pub.dzne.de/record/280021/files/DZNE-2025-00865%20SUP1.pdf
856 4 _ |u https://pub.dzne.de/record/280021/files/DZNE-2025-00865%20SUP2.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/280021/files/DZNE-2025-00865.pdf
856 4 _ |u https://pub.dzne.de/record/280021/files/DZNE-2025-00865%20SUP2.doc
856 4 _ |u https://pub.dzne.de/record/280021/files/DZNE-2025-00865%20SUP2.odt
856 4 _ |u https://pub.dzne.de/record/280021/files/DZNE-2025-00865%20SUP2.pdf
856 4 _ |x pdfa
|u https://pub.dzne.de/record/280021/files/DZNE-2025-00865%20SUP1.pdf?subformat=pdfa
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/280021/files/DZNE-2025-00865.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:280021
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 21
|6 P:(DE-2719)2811659
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 33
|6 P:(DE-2719)2811275
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-06
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2025-01-06
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-06
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ALZHEIMERS DEMENT : 2022
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-06
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-06
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-06
920 1 _ |0 I:(DE-2719)1111016
|k AG Levin
|l Clinical Neurodegeneration
|x 0
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1111016
980 _ _ |a I:(DE-2719)1111015
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21